{"transactions":[{"id":4638153,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-08T22:27:56.000Z","date":"2026-10-08","kind":"purchase","planned":false,"acquired":true,"shares":2256,"price":1.3283,"value":2996.6448,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":945924,"source":{"system":"sec-edgar","filing":"0001940272-26-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000023/primary_doc.xml","form_type":"4"}},{"id":4638152,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-08T22:27:56.000Z","date":"2026-10-07","kind":"purchase","planned":false,"acquired":true,"shares":3046,"price":1.33,"value":4051.18,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":943668,"source":{"system":"sec-edgar","filing":"0001940272-26-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000023/primary_doc.xml","form_type":"4"}},{"id":4638151,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-08T22:27:56.000Z","date":"2026-10-06","kind":"purchase","planned":false,"acquired":true,"shares":5601,"price":1.3277,"value":7436.4477,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":940622,"source":{"system":"sec-edgar","filing":"0001940272-26-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000023/primary_doc.xml","form_type":"4"}},{"id":4630729,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T21:11:48.000Z","date":"2026-10-05","kind":"purchase","planned":false,"acquired":true,"shares":18182,"price":1.33,"value":24182.06,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":935021,"source":{"system":"sec-edgar","filing":"0001940272-26-000022","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000022/primary_doc.xml","form_type":"4"}},{"id":4630728,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T21:11:48.000Z","date":"2026-10-02","kind":"purchase","planned":false,"acquired":true,"shares":8307,"price":1.33,"value":11048.31,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":916839,"source":{"system":"sec-edgar","filing":"0001940272-26-000022","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000022/primary_doc.xml","form_type":"4"}},{"id":4630727,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T21:11:48.000Z","date":"2026-10-01","kind":"purchase","planned":false,"acquired":true,"shares":16431,"price":1.3298,"value":21849.9438,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":908532,"source":{"system":"sec-edgar","filing":"0001940272-26-000022","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000022/primary_doc.xml","form_type":"4"}},{"id":4620098,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-09-16T22:58:22.000Z","date":"2026-09-16","kind":"purchase","planned":false,"acquired":true,"shares":8340,"price":1.289,"value":10750.26,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2600 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":892101,"source":{"system":"sec-edgar","filing":"0001940272-26-000021","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000021/primary_doc.xml","form_type":"4"}},{"id":4620097,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-09-16T22:58:22.000Z","date":"2026-09-15","kind":"purchase","planned":false,"acquired":true,"shares":54256,"price":1.2984,"value":70445.9904,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2800 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":883761,"source":{"system":"sec-edgar","filing":"0001940272-26-000021","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000021/primary_doc.xml","form_type":"4"}},{"id":4620096,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-09-16T22:58:22.000Z","date":"2026-09-14","kind":"purchase","planned":false,"acquired":true,"shares":28505,"price":1.2938,"value":36879.769,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2900 to $1.3100, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":829505,"source":{"system":"sec-edgar","filing":"0001940272-26-000021","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000021/primary_doc.xml","form_type":"4"}},{"id":707014,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T23:29:29.000Z","date":"2026-07-15","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":1.555,"value":1555.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":801000,"source":{"system":"sec-edgar","filing":"0001940272-26-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000010/primary_doc.xml","form_type":"4"}},{"id":708156,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":2,"price":1.55,"value":3.1,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":75019,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708155,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-16","kind":"purchase","planned":false,"acquired":true,"shares":19,"price":1.55,"value":29.45,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":743057,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708154,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-15","kind":"purchase","planned":false,"acquired":true,"shares":1389,"price":1.55,"value":2152.95,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":75017,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708153,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-15","kind":"purchase","planned":false,"acquired":true,"shares":13761,"price":1.55,"value":21329.55,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":743038,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708152,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-14","kind":"purchase","planned":false,"acquired":true,"shares":493,"price":1.55,"value":764.15,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":73628,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":708151,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-17T01:58:22.000Z","date":"2026-07-14","kind":"purchase","planned":false,"acquired":true,"shares":4882,"price":1.55,"value":7567.1,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":729277,"source":{"system":"sec-edgar","filing":"0001213900-26-078891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026078891/ownership.xml","form_type":"4"}},{"id":718357,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-07-02","kind":"purchase","planned":false,"acquired":true,"shares":147,"price":1.55,"value":227.85,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":73135,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718356,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-07-02","kind":"purchase","planned":false,"acquired":true,"shares":1460,"price":1.55,"value":2263.0,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":724395,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718355,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":398,"price":1.55,"value":616.9,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":72988,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718354,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":3946,"price":1.55,"value":6116.3,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":722935,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718353,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":55,"price":1.54,"value":84.7,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":72590,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":718352,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:02:11.000Z","date":"2026-06-30","kind":"purchase","planned":false,"acquired":true,"shares":545,"price":1.54,"value":839.3,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":718989,"source":{"system":"sec-edgar","filing":"0001213900-26-075144","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026075144/ownership.xml","form_type":"4"}},{"id":743340,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-08","kind":"purchase","planned":false,"acquired":true,"shares":2982,"price":1.52,"value":4532.64,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":72535,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743339,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-08","kind":"purchase","planned":false,"acquired":true,"shares":29518,"price":1.52,"value":44867.36,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":718444,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743338,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-05","kind":"purchase","planned":false,"acquired":true,"shares":5045,"price":1.57,"value":7920.65,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":69553,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743337,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-05","kind":"purchase","planned":false,"acquired":true,"shares":49966,"price":1.57,"value":78446.62,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":688926,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743336,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-04","kind":"purchase","planned":false,"acquired":true,"shares":618,"price":1.57,"value":970.26,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":64508,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743335,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-04","kind":"purchase","planned":false,"acquired":true,"shares":6125,"price":1.57,"value":9616.25,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":638960,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743334,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-03","kind":"purchase","planned":false,"acquired":true,"shares":714,"price":1.55,"value":1106.7,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":63890,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743333,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-03","kind":"purchase","planned":false,"acquired":true,"shares":7069,"price":1.55,"value":10956.95,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":632835,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743332,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-02","kind":"purchase","planned":false,"acquired":true,"shares":2095,"price":1.52,"value":3184.4,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":63176,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743331,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-02","kind":"purchase","planned":false,"acquired":true,"shares":20753,"price":1.52,"value":31544.56,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":625766,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743330,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":1498,"price":1.55,"value":2321.9,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":61081,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743329,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":14838,"price":1.55,"value":22998.9,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":605013,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743328,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-29","kind":"purchase","planned":false,"acquired":true,"shares":1632,"price":1.57,"value":2562.24,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":59583,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743327,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-29","kind":"purchase","planned":false,"acquired":true,"shares":16164,"price":1.57,"value":25377.48,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":590175,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743326,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-21","kind":"purchase","planned":false,"acquired":true,"shares":3118,"price":1.69,"value":5269.42,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":57951,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743325,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-21","kind":"purchase","planned":false,"acquired":true,"shares":30882,"price":1.69,"value":52190.58,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":574011,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743324,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-20","kind":"purchase","planned":false,"acquired":true,"shares":5154,"price":1.56,"value":8040.24,"ownership":{"direct":false,"nature":"By Vivo Opportunity Cayman Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":54833,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":743323,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":30106,"kind":"organization","name":"Vivo Opportunity, LLC","position":1,"cik":"0001728970","reported_name":"Vivo Opportunity, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30107,"kind":"organization","name":"Vivo Opportunity Fund Holdings, L.P.","position":2,"cik":"0001930214","reported_name":"Vivo Opportunity Fund Holdings, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30108,"kind":"organization","name":"Vivo Opportunity Cayman, LLC","position":3,"cik":"0001930113","reported_name":"Vivo Opportunity Cayman, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30109,"kind":"organization","name":"Vivo Opportunity Cayman Fund, L.P.","position":4,"cik":"0001875722","reported_name":"Vivo Opportunity Cayman Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-06-11T01:14:46.000Z","date":"2026-05-20","kind":"purchase","planned":false,"acquired":true,"shares":51056,"price":1.56,"value":79647.36,"ownership":{"direct":false,"nature":"By Vivo Opportunity Fund Holdings, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":543129,"source":{"system":"sec-edgar","filing":"0001213900-26-067505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875722/000121390026067505/ownership.xml","form_type":"4"}},{"id":768196,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-05-21T21:08:05.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":1.499,"value":299800.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.4350 to $1.5700, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":800000,"source":{"system":"sec-edgar","filing":"0001940272-26-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000008/primary_doc.xml","form_type":"4"}},{"id":768195,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-05-21T21:08:05.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":1.5604,"value":312080.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5100 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":600000,"source":{"system":"sec-edgar","filing":"0001940272-26-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000008/primary_doc.xml","form_type":"4"}},{"id":768194,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":980,"kind":"organization","name":"ADAR1 Capital Management, LLC","position":1,"cik":"0001940272","reported_name":"ADAR1 Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":981,"kind":"person","name":"Schneeberger Daniel","position":2,"cik":"0001861120","reported_name":"Schneeberger Daniel","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2026-05-21T21:08:05.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":68551,"price":1.5998,"value":109667.8898,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5700 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0001940272-26-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940272/000194027226000008/primary_doc.xml","form_type":"4"}},{"id":961746,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71073,"kind":"person","name":"Johnson Shane Aaron","position":1,"cik":"0001889332","reported_name":"Johnson Shane Aaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP & General Manager"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T16:42:54.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month)"}],"balance_after":12400,"derivative":{"exercise_price":1.29,"expiration_date":"2030-12-18","underlying":"Common shares","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001213900-25-123639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025123639/ownership.xml","form_type":"4"}},{"id":961745,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":35347,"kind":"person","name":"Lemerond Nicole","position":1,"cik":"0001941712","reported_name":"Lemerond Nicole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T16:42:35.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner."}],"balance_after":2725,"derivative":{"exercise_price":1.29,"expiration_date":"2030-12-18","underlying":"Common shares","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001213900-25-123637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025123637/ownership.xml","form_type":"4"}},{"id":961744,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71072,"kind":"person","name":"Klompas Neil A","position":1,"cik":"0001761857","reported_name":"Klompas Neil A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T16:42:16.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner."}],"balance_after":5250,"derivative":{"exercise_price":1.29,"expiration_date":"2030-12-18","underlying":"Common shares","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001213900-25-123636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025123636/ownership.xml","form_type":"4"}},{"id":961743,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71071,"kind":"person","name":"Bathery John Steven","position":1,"cik":"0002093653","reported_name":"Bathery John Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T16:40:23.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner."}],"balance_after":5250,"derivative":{"exercise_price":1.29,"expiration_date":"2030-12-18","underlying":"Common shares","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001213900-25-123630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025123630/ownership.xml","form_type":"4"}},{"id":962193,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71109,"kind":"person","name":"Jagpal Netta","position":1,"cik":"0002013468","reported_name":"Jagpal Netta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T11:41:51.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month)"}],"balance_after":24250,"derivative":{"exercise_price":1.29,"expiration_date":"2030-12-18","underlying":"Common shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001213900-25-123635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013468/000121390025123635/ownership.xml","form_type":"4"}},{"id":962100,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71097,"kind":"person","name":"WOUDENBERG MICHAEL","position":1,"cik":"0001817884","reported_name":"WOUDENBERG MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T11:41:09.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month)"}],"balance_after":25445,"derivative":{"exercise_price":1.29,"expiration_date":"2030-12-18","underlying":"Common shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001213900-25-123633","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817884/000121390025123633/ownership.xml","form_type":"4"}},{"id":962105,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71101,"kind":"person","name":"HSU ERIC C","position":1,"cik":"0001817867","reported_name":"HSU ERIC C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Pre-Clinical Res/Dev"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T11:39:39.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month)"}],"balance_after":18280,"derivative":{"exercise_price":1.29,"expiration_date":"2030-12-18","underlying":"Common shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001213900-25-123628","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817867/000121390025123628/ownership.xml","form_type":"4"}},{"id":962102,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71099,"kind":"person","name":"ADAMS ERIC A","position":1,"cik":"0001817882","reported_name":"ADAMS ERIC A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T11:39:04.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month)"}],"balance_after":49050,"derivative":{"exercise_price":1.29,"expiration_date":"2030-12-18","underlying":"Common shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-123625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817882/000121390025123625/ownership.xml","form_type":"4"}},{"id":962101,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71098,"kind":"person","name":"HULL ANDREW","position":1,"cik":"0001818252","reported_name":"HULL ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T11:38:13.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner."}],"balance_after":2711,"derivative":{"exercise_price":1.29,"expiration_date":"2030-12-18","underlying":"Common shares","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001213900-25-123620","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818252/000121390025123620/ownership.xml","form_type":"4"}},{"id":965169,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71098,"kind":"person","name":"HULL ANDREW","position":1,"cik":"0001818252","reported_name":"HULL ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Expiration)","published_at":"2025-12-17T12:20:20.000Z","date":"2025-12-15","kind":"other","planned":false,"acquired":false,"shares":14,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00"}],"balance_after":961,"derivative":{"exercise_price":1397.97,"exercise_date":"2020-12-16","expiration_date":"2025-12-15","underlying":"Common shares","underlying_shares":14},"source":{"system":"sec-edgar","filing":"0001213900-25-122649","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818252/000121390025122649/ownership.xml","form_type":"4"}},{"id":965171,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71099,"kind":"person","name":"ADAMS ERIC A","position":1,"cik":"0001817882","reported_name":"ADAMS ERIC A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Expiration)","published_at":"2025-12-17T12:19:09.000Z","date":"2025-12-15","kind":"other","planned":false,"acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00"}],"balance_after":14050,"derivative":{"exercise_price":1397.97,"exercise_date":"2020-12-16","expiration_date":"2025-12-15","underlying":"Common shares","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001213900-25-122647","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817882/000121390025122647/ownership.xml","form_type":"4"}},{"id":965168,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71097,"kind":"person","name":"WOUDENBERG MICHAEL","position":1,"cik":"0001817884","reported_name":"WOUDENBERG MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Expiration)","published_at":"2025-12-17T12:17:57.000Z","date":"2025-12-15","kind":"other","planned":false,"acquired":false,"shares":60,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00"}],"balance_after":7445,"derivative":{"exercise_price":1397.97,"exercise_date":"2020-12-16","expiration_date":"2025-12-15","underlying":"Common shares","underlying_shares":60},"source":{"system":"sec-edgar","filing":"0001213900-25-122645","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817884/000121390025122645/ownership.xml","form_type":"4"}},{"id":965170,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71101,"kind":"person","name":"HSU ERIC C","position":1,"cik":"0001817867","reported_name":"HSU ERIC C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Pre-Clinical Res/Dev"}}],"security":"Employee Stock Option (Expiration)","published_at":"2025-12-17T12:16:23.000Z","date":"2025-12-15","kind":"other","planned":false,"acquired":false,"shares":70,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00"}],"balance_after":5280,"derivative":{"exercise_price":1397.97,"exercise_date":"2020-12-16","expiration_date":"2025-12-15","underlying":"Common shares","underlying_shares":70},"source":{"system":"sec-edgar","filing":"0001213900-25-122641","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817867/000121390025122641/ownership.xml","form_type":"4"}},{"id":1015115,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71072,"kind":"person","name":"Klompas Neil A","position":1,"cik":"0001761857","reported_name":"Klompas Neil A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-10-21T17:58:38.000Z","date":"2025-10-17","kind":"grant","planned":false,"acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(1) The options were granted on Oct 17, 2025 and will vest monthly, in arrears, as follows:\n\n(i) 98 stock options will vest on the 17th day of each month for 35 months, and\n(ii) 70 stock options will vest on Oct 17, 2025 (the three year anniversary of Grant date)."}],"balance_after":3500,"derivative":{"exercise_price":2.1,"expiration_date":"2030-10-16","underlying":"Common shares","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001213900-25-100720","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025100720/ownership.xml","form_type":"4"}},{"id":1287538,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71098,"kind":"person","name":"HULL ANDREW","position":1,"cik":"0001818252","reported_name":"HULL ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Expiration)","published_at":"2025-02-03T08:49:05.000Z","date":"2025-01-11","kind":"other","planned":false,"acquired":false,"shares":2,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$4,125.00 using an exchange rate of C$1.4422 = $US1.00"}],"balance_after":975,"derivative":{"exercise_price":2860.21,"exercise_date":"2020-01-12","expiration_date":"2025-01-11","underlying":"Common shares","underlying_shares":2},"source":{"system":"sec-edgar","filing":"0001213900-25-009136","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818252/000121390025009136/ownership.xml","form_type":"4"}},{"id":1322544,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71073,"kind":"person","name":"Johnson Shane Aaron","position":1,"cik":"0001889332","reported_name":"Johnson Shane Aaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP & General Manager"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-23T14:28:12.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/20/2024 and will vest in equal installments monthly over 36 months (1/36 per month)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split."}],"balance_after":3900,"derivative":{"exercise_price":4.14,"expiration_date":"2029-12-19","underlying":"Common shares","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001213900-24-111570","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024111570/ownership.xml","form_type":"4"}},{"id":1322543,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":35347,"kind":"person","name":"Lemerond Nicole","position":1,"cik":"0001941712","reported_name":"Lemerond Nicole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-23T14:25:28.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split."}],"balance_after":975,"derivative":{"exercise_price":4.14,"expiration_date":"2029-12-19","underlying":"Common shares","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001213900-24-111566","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024111566/ownership.xml","form_type":"4"}},{"id":1323093,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71109,"kind":"person","name":"Jagpal Netta","position":1,"cik":"0002013468","reported_name":"Jagpal Netta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-23T09:26:50.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/20/2024 and will vest in equal installments monthly over 36 months (1/36 per month)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split."}],"balance_after":6250,"derivative":{"exercise_price":4.14,"expiration_date":"2029-12-19","underlying":"Common shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001213900-24-111568","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013468/000121390024111568/ownership.xml","form_type":"4"}},{"id":1322919,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71097,"kind":"person","name":"WOUDENBERG MICHAEL","position":1,"cik":"0001817884","reported_name":"WOUDENBERG MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-23T09:24:14.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/20/2024 and will vest in equal installments monthly over 36 months (1/36 per month)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split."}],"balance_after":7505,"derivative":{"exercise_price":4.14,"expiration_date":"2029-12-19","underlying":"Common shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001213900-24-111563","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817884/000121390024111563/ownership.xml","form_type":"4"}},{"id":1322669,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":84809,"kind":"person","name":"Grove Janet P","position":1,"cik":"0001355675","reported_name":"Grove Janet P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-23T09:22:58.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split."}],"balance_after":975,"derivative":{"exercise_price":4.14,"expiration_date":"2029-12-19","underlying":"Common shares","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001213900-24-111558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1355675/000121390024111558/ownership.xml","form_type":"4"}},{"id":1322922,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71101,"kind":"person","name":"HSU ERIC C","position":1,"cik":"0001817867","reported_name":"HSU ERIC C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Pre-Clinical Res/Dev"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-23T09:21:36.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/20/2024 and will vest in equal installments monthly over 36 months (1/36 per month)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split."}],"balance_after":5350,"derivative":{"exercise_price":4.14,"expiration_date":"2029-12-19","underlying":"Common shares","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001213900-24-111554","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817867/000121390024111554/ownership.xml","form_type":"4"}},{"id":1322921,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71099,"kind":"person","name":"ADAMS ERIC A","position":1,"cik":"0001817882","reported_name":"ADAMS ERIC A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-23T09:20:10.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/20/2024 and will vest in equal installments monthly over 36 months (1/36 per month)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split."}],"balance_after":14300,"derivative":{"exercise_price":4.14,"expiration_date":"2029-12-19","underlying":"Common shares","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001213900-24-111552","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817882/000121390024111552/ownership.xml","form_type":"4"}},{"id":1322896,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":84826,"kind":"person","name":"Baldasare Bryan T","position":1,"cik":"0001761920","reported_name":"Baldasare Bryan T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-23T09:18:56.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split."}],"balance_after":975,"derivative":{"exercise_price":4.14,"expiration_date":"2029-12-19","underlying":"Common shares","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001213900-24-111548","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761920/000121390024111548/ownership.xml","form_type":"4"}},{"id":1322920,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71098,"kind":"person","name":"HULL ANDREW","position":1,"cik":"0001818252","reported_name":"HULL ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-23T09:17:37.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split."}],"balance_after":977,"derivative":{"exercise_price":4.14,"expiration_date":"2029-12-19","underlying":"Common shares","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001213900-24-111543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818252/000121390024111543/ownership.xml","form_type":"4"}},{"id":1443005,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":88535,"kind":"person","name":"MANCINI ALEXANDRA DIANE JANET","position":1,"cik":"0001817890","reported_name":"MANCINI ALEXANDRA DIANE JANET","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Consultant"}}],"security":"Common Stock","published_at":"2024-08-02T16:02:46.000Z","date":"2024-07-31","kind":"sale","planned":false,"acquired":false,"shares":240,"price":0.1763,"value":42.312,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-24-064728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817890/000121390024064728/ownership.xml","form_type":"4"}},{"id":1500565,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71097,"kind":"person","name":"WOUDENBERG MICHAEL","position":1,"cik":"0001817884","reported_name":"WOUDENBERG MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Expiration)","published_at":"2024-05-28T16:27:14.000Z","date":"2024-05-27","kind":"other","planned":false,"acquired":false,"shares":394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$358.875 using an exchange rate of C$1.3636 (as of May 27th, 2024) = $US1.00"}],"balance_after":75100,"derivative":{"exercise_price":263.18,"exercise_date":"2019-05-27","expiration_date":"2024-05-27","underlying":"Common shares","underlying_shares":394},"source":{"system":"sec-edgar","filing":"0001213900-24-047096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817884/000121390024047096/ownership.xml","form_type":"4"}},{"id":1500569,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71101,"kind":"person","name":"HSU ERIC C","position":1,"cik":"0001817867","reported_name":"HSU ERIC C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Pre-Clinical Res/Dev"}}],"security":"Employee Stock Option (Expiration)","published_at":"2024-05-28T16:26:47.000Z","date":"2024-05-27","kind":"other","planned":false,"acquired":false,"shares":545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$358.875 using an exchange rate of C$1.3636 (as of May 27th, 2024) = $US1.00"}],"balance_after":52000,"derivative":{"exercise_price":263.18,"exercise_date":"2019-05-27","expiration_date":"2024-05-27","underlying":"Common shares","underlying_shares":545},"source":{"system":"sec-edgar","filing":"0001213900-24-047095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817867/000121390024047095/ownership.xml","form_type":"4"}},{"id":1500567,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71099,"kind":"person","name":"ADAMS ERIC A","position":1,"cik":"0001817882","reported_name":"ADAMS ERIC A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Expiration)","published_at":"2024-05-28T16:26:32.000Z","date":"2024-05-27","kind":"other","planned":false,"acquired":false,"shares":1139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$358.875 using an exchange rate of C$1.3636 (as of May 27th, 2024) = $US1.00"}],"balance_after":161000,"derivative":{"exercise_price":263.18,"exercise_date":"2019-05-27","expiration_date":"2024-05-27","underlying":"Common shares","underlying_shares":1139},"source":{"system":"sec-edgar","filing":"0001213900-24-047094","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817882/000121390024047094/ownership.xml","form_type":"4"}},{"id":1500566,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":88535,"kind":"person","name":"MANCINI ALEXANDRA DIANE JANET","position":1,"cik":"0001817890","reported_name":"MANCINI ALEXANDRA DIANE JANET","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP, Clinical Reg Affairs"}}],"security":"Employee Stock Option (Expiration)","published_at":"2024-05-28T16:26:17.000Z","date":"2024-05-27","kind":"other","planned":false,"acquired":false,"shares":485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$358.875 using an exchange rate of C$1.3636 (as of May 27th, 2024) = $US1.00"}],"balance_after":52000,"derivative":{"exercise_price":263.18,"exercise_date":"2019-05-27","expiration_date":"2024-05-27","underlying":"Common shares","underlying_shares":485},"source":{"system":"sec-edgar","filing":"0001213900-24-047093","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817890/000121390024047093/ownership.xml","form_type":"4"}},{"id":1597087,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71098,"kind":"person","name":"HULL ANDREW","position":1,"cik":"0001818252","reported_name":"HULL ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Expiration)","published_at":"2024-03-05T15:20:52.000Z","date":"2024-01-14","kind":"other","planned":false,"acquired":false,"shares":42,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$412.50 using an exchange rate of C$1.3436 = $US1.00"}],"balance_after":8542,"derivative":{"exercise_price":307.01,"exercise_date":"2019-01-14","expiration_date":"2024-01-14","underlying":"Common shares","underlying_shares":42},"source":{"system":"sec-edgar","filing":"0001213900-24-020088","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818252/000121390024020088/ownership.xml","form_type":"4"}},{"id":1597089,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71101,"kind":"person","name":"HSU ERIC C","position":1,"cik":"0001817867","reported_name":"HSU ERIC C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Pre-Clinical Res/Dev"}}],"security":"Employee Stock Option (Expiration)","published_at":"2024-03-05T15:20:38.000Z","date":"2024-03-04","kind":"other","planned":false,"acquired":false,"shares":309,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$495 using an exchange rate of C$1.3572 = $US1.00"}],"balance_after":52545,"derivative":{"exercise_price":364.72,"exercise_date":"2019-03-04","expiration_date":"2024-03-04","underlying":"Common shares","underlying_shares":309},"source":{"system":"sec-edgar","filing":"0001213900-24-020087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817867/000121390024020087/ownership.xml","form_type":"4"}},{"id":1597088,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":88535,"kind":"person","name":"MANCINI ALEXANDRA DIANE JANET","position":1,"cik":"0001817890","reported_name":"MANCINI ALEXANDRA DIANE JANET","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP, Clinical Reg Affairs"}}],"security":"Employee Stock Option (Expiration)","published_at":"2024-03-05T15:20:23.000Z","date":"2024-01-21","kind":"other","planned":false,"acquired":false,"shares":121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$420.75 using an exchange rate of C$1.3454 = $US1.00"}],"balance_after":52485,"derivative":{"exercise_price":312.73,"exercise_date":"2019-01-21","expiration_date":"2024-01-21","underlying":"Common shares","underlying_shares":121},"source":{"system":"sec-edgar","filing":"0001213900-24-020086","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817890/000121390024020086/ownership.xml","form_type":"4"}},{"id":1625535,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71098,"kind":"person","name":"HULL ANDREW","position":1,"cik":"0001818252","reported_name":"HULL ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-22T13:38:46.000Z","date":"2024-02-21","kind":"purchase","planned":false,"acquired":true,"shares":37500,"price":0.39,"value":14625.0,"ownership":{"direct":true},"balance_after":38258,"source":{"system":"sec-edgar","filing":"0001213900-24-016026","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818252/000121390024016026/ownership.xml","form_type":"4"}},{"id":1629596,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71099,"kind":"person","name":"ADAMS ERIC A","position":1,"cik":"0001817882","reported_name":"ADAMS ERIC A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-02-21T14:58:17.000Z","date":"2024-02-20","kind":"purchase","planned":false,"acquired":true,"shares":41600,"price":0.3587,"value":14921.92,"ownership":{"direct":true},"balance_after":43959,"source":{"system":"sec-edgar","filing":"0001213900-24-015703","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817882/000121390024015703/ownership.xml","form_type":"4"}},{"id":1699949,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71073,"kind":"person","name":"Johnson Shane Aaron","position":1,"cik":"0001889332","reported_name":"Johnson Shane Aaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP & General Manager"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T18:09:48.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month)."}],"balance_after":48000,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-23-098497","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390023098497/ownership.xml","form_type":"4"}},{"id":1699948,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":35347,"kind":"person","name":"Lemerond Nicole","position":1,"cik":"0001941712","reported_name":"Lemerond Nicole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T18:09:25.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":7100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest 100% on the one-year anniversary of the grant date (December 23, 2024) or immediately prior to the next Annual General Meeting, whichever is sooner."}],"balance_after":8500,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001213900-23-098495","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390023098495/ownership.xml","form_type":"4"}},{"id":1699947,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":95823,"kind":"person","name":"Tegge Jonathan","position":1,"cik":"0001755310","reported_name":"Tegge Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T18:08:36.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month)."}],"balance_after":31400,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-23-098492","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390023098492/ownership.xml","form_type":"4"}},{"id":1700184,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71097,"kind":"person","name":"WOUDENBERG MICHAEL","position":1,"cik":"0001817884","reported_name":"WOUDENBERG MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T13:09:00.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month)."}],"balance_after":75494,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001213900-23-098494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817884/000121390023098494/ownership.xml","form_type":"4"}},{"id":1700000,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":84809,"kind":"person","name":"Grove Janet P","position":1,"cik":"0001355675","reported_name":"Grove Janet P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T13:08:13.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":7100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest 100% on the one-year anniversary of the grant date (December 23, 2024) or immediately prior to the next Annual General Meeting, whichever is sooner."}],"balance_after":8500,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001213900-23-098491","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1355675/000121390023098491/ownership.xml","form_type":"4"}},{"id":1700188,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71101,"kind":"person","name":"HSU ERIC C","position":1,"cik":"0001817867","reported_name":"HSU ERIC C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Pre-Clinical Res/Dev"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T13:07:44.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month)."}],"balance_after":52854,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001213900-23-098490","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817867/000121390023098490/ownership.xml","form_type":"4"}},{"id":1700187,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71099,"kind":"person","name":"ADAMS ERIC A","position":1,"cik":"0001817882","reported_name":"ADAMS ERIC A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T13:07:20.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":136000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month)."}],"balance_after":162139,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":136000},"source":{"system":"sec-edgar","filing":"0001213900-23-098489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817882/000121390023098489/ownership.xml","form_type":"4"}},{"id":1700103,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":84826,"kind":"person","name":"Baldasare Bryan T","position":1,"cik":"0001761920","reported_name":"Baldasare Bryan T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T13:05:14.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":7100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest 100% on the one-year anniversary of the grant date (December 23, 2024) or immediately prior to the next Annual General Meeting, whichever is sooner."}],"balance_after":8500,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001213900-23-098488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1761920/000121390023098488/ownership.xml","form_type":"4"}},{"id":1700186,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":88535,"kind":"person","name":"MANCINI ALEXANDRA DIANE JANET","position":1,"cik":"0001817890","reported_name":"MANCINI ALEXANDRA DIANE JANET","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP, Clinical Reg Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T13:04:50.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month)."}],"balance_after":52606,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001213900-23-098487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817890/000121390023098487/ownership.xml","form_type":"4"}},{"id":1700185,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71098,"kind":"person","name":"HULL ANDREW","position":1,"cik":"0001818252","reported_name":"HULL ANDREW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-12-26T13:04:18.000Z","date":"2023-12-23","kind":"grant","planned":false,"acquired":true,"shares":7100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/23/2023 and will vest 100% on the one-year anniversary of the grant date (December 23, 2024) or immediately prior to the next Annual General Meeting, whichever is sooner."}],"balance_after":8584,"derivative":{"exercise_price":0.37,"expiration_date":"2028-12-22","underlying":"Common shares","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001213900-23-098486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818252/000121390023098486/ownership.xml","form_type":"4"}},{"id":1720171,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71097,"kind":"person","name":"WOUDENBERG MICHAEL","position":1,"cik":"0001817884","reported_name":"WOUDENBERG MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Expiration)","published_at":"2023-12-06T09:02:25.000Z","date":"2023-12-05","kind":"other","planned":false,"acquired":false,"shares":848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$367.125 using an exchange rate of C$1.3579 = $US1.00"}],"balance_after":10494,"derivative":{"exercise_price":270.36,"exercise_date":"2018-12-05","expiration_date":"2023-12-05","underlying":"Common shares","underlying_shares":848},"source":{"system":"sec-edgar","filing":"0001213900-23-093299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817884/000121390023093299/ownership.xml","form_type":"4"}},{"id":1792044,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71101,"kind":"person","name":"HSU ERIC C","position":1,"cik":"0001817867","reported_name":"HSU ERIC C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Pre-Clinical Res/Dev"}}],"security":"Employee Stock Option (Expiration)","published_at":"2023-08-31T17:22:15.000Z","date":"2023-08-31","kind":"other","planned":false,"acquired":false,"shares":327,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$676.50 using an exchange rate of C$1.3531 = $US1.00"}],"balance_after":7854,"derivative":{"exercise_price":499.96,"exercise_date":"2018-08-31","expiration_date":"2023-08-31","underlying":"Common shares","underlying_shares":327},"source":{"system":"sec-edgar","filing":"0001213900-23-072856","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817867/000121390023072856/ownership.xml","form_type":"4"}},{"id":1891696,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71101,"kind":"person","name":"HSU ERIC C","position":1,"cik":"0001817867","reported_name":"HSU ERIC C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Pre-Clinical Res/Dev"}}],"security":"Employee Stock Option (Expiration)","published_at":"2023-05-16T18:00:00.000Z","date":"2023-05-16","kind":"other","planned":false,"acquired":false,"shares":152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$841.50 using an exchange rate of C$1.3487 = $US1.00"}],"balance_after":8181,"derivative":{"exercise_price":623.93,"exercise_date":"2018-05-16","expiration_date":"2023-05-16","underlying":"Common shares","underlying_shares":152},"source":{"system":"sec-edgar","filing":"0001213900-23-040579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817867/000121390023040579/ownership.xml","form_type":"4"}},{"id":1891694,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":88535,"kind":"person","name":"MANCINI ALEXANDRA DIANE JANET","position":1,"cik":"0001817890","reported_name":"MANCINI ALEXANDRA DIANE JANET","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP, Clinical Reg Affairs"}}],"security":"Employee Stock Option (Expiration)","published_at":"2023-05-16T17:59:25.000Z","date":"2023-05-16","kind":"other","planned":false,"acquired":false,"shares":485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$841.50 using an exchange rate of C$1.3487 = $US1.00"}],"balance_after":7606,"derivative":{"exercise_price":623.93,"exercise_date":"2018-05-16","expiration_date":"2023-05-16","underlying":"Common shares","underlying_shares":485},"source":{"system":"sec-edgar","filing":"0001213900-23-040578","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817890/000121390023040578/ownership.xml","form_type":"4"}},{"id":1891695,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71099,"kind":"person","name":"ADAMS ERIC A","position":1,"cik":"0001817882","reported_name":"ADAMS ERIC A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Expiration)","published_at":"2023-05-16T17:58:35.000Z","date":"2023-05-16","kind":"other","planned":false,"acquired":false,"shares":1818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$841.50 using an exchange rate of C$1.3487 = $US1.00"}],"balance_after":26139,"derivative":{"exercise_price":623.93,"exercise_date":"2018-05-16","expiration_date":"2023-05-16","underlying":"Common shares","underlying_shares":1818},"source":{"system":"sec-edgar","filing":"0001213900-23-040577","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817882/000121390023040577/ownership.xml","form_type":"4"}},{"id":1961188,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":88535,"kind":"person","name":"MANCINI ALEXANDRA DIANE JANET","position":1,"cik":"0001817890","reported_name":"MANCINI ALEXANDRA DIANE JANET","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP, Clinical Reg Affairs"}}],"security":"Employee Stock Option (Expiration)","published_at":"2023-03-09T15:47:38.000Z","date":"2023-03-08","kind":"other","acquired":false,"shares":61,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$1,278.75 using an exchange rate of C$1.3785 = $US1.00"}],"balance_after":8091,"derivative":{"exercise_price":927.64,"exercise_date":"2018-03-08","expiration_date":"2023-03-08","underlying":"Common shares","underlying_shares":61},"source":{"system":"sec-edgar","filing":"0001213900-23-018871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817890/000121390023018871/ownership.xml","form_type":"4"}},{"id":1961190,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71101,"kind":"person","name":"HSU ERIC C","position":1,"cik":"0001817867","reported_name":"HSU ERIC C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Pre-Clinical Res/Dev"}}],"security":"Employee Stock Option (Expiration)","published_at":"2023-03-09T15:45:53.000Z","date":"2023-03-08","kind":"other","acquired":false,"shares":545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$1,278.75 using an exchange rate of C$1.3785 = $US1.00"}],"balance_after":8333,"derivative":{"exercise_price":927.64,"exercise_date":"2018-03-08","expiration_date":"2023-03-08","underlying":"Common shares","underlying_shares":545},"source":{"system":"sec-edgar","filing":"0001213900-23-018869","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817867/000121390023018869/ownership.xml","form_type":"4"}},{"id":1961189,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71099,"kind":"person","name":"ADAMS ERIC A","position":1,"cik":"0001817882","reported_name":"ADAMS ERIC A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Expiration)","published_at":"2023-03-09T15:43:46.000Z","date":"2023-03-08","kind":"other","acquired":false,"shares":545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Converted from the Canadian dollar exercise price of C$1,278.75 using an exchange rate of C$1.3785 = $US1.00"}],"balance_after":27957,"derivative":{"exercise_price":927.64,"exercise_date":"2018-03-08","expiration_date":"2023-03-08","underlying":"Common shares","underlying_shares":545},"source":{"system":"sec-edgar","filing":"0001213900-23-018866","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817882/000121390023018866/ownership.xml","form_type":"4"}},{"id":2081015,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":35347,"kind":"person","name":"Lemerond Nicole","position":1,"cik":"0001941712","reported_name":"Lemerond Nicole","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-12-19T22:08:34.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/16/2022 and will vest as follows: Vesting 100% on the one-year anniversary of the grant date (Dec 16, 2023) or immediately prior to the next AGM, whichever is sooner."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split."}],"balance_after":1400,"derivative":{"exercise_price":1.78,"expiration_date":"2027-12-15","underlying":"Common shares","underlying_shares":840},"source":{"system":"sec-edgar","filing":"0001213900-22-080987","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022080987/ownership.xml","form_type":"4"}},{"id":2081014,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":95823,"kind":"person","name":"Tegge Jonathan","position":1,"cik":"0001755310","reported_name":"Tegge Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-12-19T22:04:34.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 1/12 per month, in arrears, for 12 months."}],"balance_after":1400,"derivative":{"exercise_price":1.78,"expiration_date":"2027-12-15","underlying":"Common shares","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001213900-22-080971","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022080971/ownership.xml","form_type":"4"}},{"id":2081013,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71073,"kind":"person","name":"Johnson Shane Aaron","position":1,"cik":"0001889332","reported_name":"Johnson Shane Aaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP & General Manager"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-12-19T21:59:53.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":4200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split."}],"balance_after":8000,"derivative":{"exercise_price":1.78,"expiration_date":"2027-12-15","underlying":"Common shares","underlying_shares":4200},"source":{"system":"sec-edgar","filing":"0001213900-22-080992","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022080992/ownership.xml","form_type":"4"}},{"id":2082144,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":121482,"kind":"person","name":"Li Sarah","position":1,"cik":"0001956288","reported_name":"Li Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Accounting & Controller"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-12-19T17:03:37.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant."}],"balance_after":4002,"derivative":{"exercise_price":1.78,"expiration_date":"2027-12-15","underlying":"Common shares","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0001213900-22-080994","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1956288/000121390022080994/ownership.xml","form_type":"4"}},{"id":2081833,"issuer":{"id":8139,"kind":"organization","name":"InMed Pharmaceuticals Inc.","symbol":"INM"},"owners":[{"id":71097,"kind":"person","name":"WOUDENBERG MICHAEL","position":1,"cik":"0001817884","reported_name":"WOUDENBERG MICHAEL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-12-19T16:58:56.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split."}],"balance_after":11342,"derivative":{"exercise_price":1.78,"expiration_date":"2027-12-15","underlying":"Common shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-22-080983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817884/000121390022080983/ownership.xml","form_type":"4"}}],"next_cursor":"2022-12-19T16:58:56.000000Z,2081833"}